Medical Economics December 14, 2023
In 2024, beneficiaries could see savings per dose, according to new guidance on price increases relative to inflation.
Prescription drug prices could drop for some patients due to rebates that pharmaceutical makers pay to the federal government.
On Dec. 14, 2023, the U.S. Centers for Medicare & Medicaid Services (CMS) published new guidance on rebates for medicines, stemming from provisions of the Inflation Reduction Act of August 2022. The law requires pharmaceutical makers to repay Medicare when certain drug prices increase faster than the rate of inflation, according to CMS.
Medicare participants could see savings ranging from $1 to $2,786 per average dose in 2024 due to the Medicare Prescription Drug Inflation Rebate Program for some drugs covered under Medicare...
Today's Sponsors
Today's Sponsor